Shares of AXT Inc. tumbled 6.7% to $113.76 on May 14 — the very day shareholders vote on a proposal to massively expand the company's share pool — as fears of further stock dilution (when a company issues new shares, shrinking every existing investor's ownership slice) collided with an AI-fueled rally that had already pushed the stock from the low $40s in early April past $125.

  • A 71% Increase in Authorized Shares Hangs Over the Vote. AXT is asking shareholders to approve raising its authorized common shares from 70 million to 120 million , with roughly 55.6 million shares currently outstanding . That would give management a blank check to issue up to 64 million additional shares without another vote. Combined with the new authorization request, it underlines how equity capital has become an important tool for supporting the business during a period of sales declines and continued net losses. For shareholders, the math is simple: more shares outstanding means each existing share commands a smaller piece of future profits.

  • AXT Already Raised $632.5 Million by Selling Stock at $64.25. In April, AXT closed an underwritten offering of 8.56 million shares at $64.25, raising roughly $550 million in gross proceeds.

Underwriters then exercised the full over-allotment option for another 1.28 million shares, bringing the total to approximately $632.5 million. That's an enormous raise for a company with under $100 million in annual revenue . And the December 2025 offering was even more jarring: AXT issued 7.1 million shares at just $12.25 each , a steep discount that set the precedent investors now fear will repeat.

  • The Business Is Improving — but Still Losing Money. Q1 2026 revenue hit $26.9 million, up from $19.4 million a year ago , and non-GAAP gross margin surged to 29.9% from negative 6.1%.

Management says the indium phosphide backlog now exceeds $100 million. Yet net loss still came in at $1.6 million , and insiders have been selling aggressively — the CEO alone dumped 547,756 shares for an estimated $17.1 million over six months.

  • China's Export Permit System Is the Wild Card. China added indium phosphide to its export control list in February 2025, requiring AXT to secure government permits for each overseas shipment , creating unpredictable revenue swings. North American revenue collapsed to just 2% of total sales in 2025.

AXT's own executives describe the permitting process as "opaque." Until that bottleneck clears, all the new capacity AXT is building with investor cash remains hostage to Beijing's approval timeline.

The stock trades at a price-to-sales ratio above 40× on trailing revenue. Analysts' average 12-month target sits at just $57 — roughly half the current price. AXT is betting that AI-driven demand will vindicate a dilution-heavy strategy; investors must decide whether the growth story justifies the ownership cost.